Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
1.
Am J Cardiovasc Dis ; 10(3): 195-200, 2020.
Article de Anglais | MEDLINE | ID: mdl-32923101

RÉSUMÉ

BACKGROUND: Kounis syndrome (KS) is defined as the occurrence of an acute coronary syndrome related to allergic or hypersensitivity reaction. KS is currently classified into three variants, based on coronary arteries status. This syndrome is often neglected or misdiagnosed in clinical practice. METHODS AND RESULTS: We described a type II KS case. This acute coronary syndrome (ACS) began with cardiac arrest (an uncommon clinical expression for KS) immediately after oral intake of amoxicilline. Coronary angiography revealed coronary arteries stenoses which were considered unsuitable for revascularization. Optimization of medical therapies was the goal of the management for this patient. Follow-up visits revealed normal echocardiographic findings and no malignant arrhythmias at ECG Holter monitoring. CONCLUSIONS: KS can be a rare case for ACS, sometimes occurring with sudden cardiac arrest. Physicians should pay attention to the history of the patients in order to identify the correct cause of ACSs.

2.
Pacing Clin Electrophysiol ; 43(7): 713-719, 2020 07.
Article de Anglais | MEDLINE | ID: mdl-32452043

RÉSUMÉ

BACKGROUND: The venous access for the insertion of permanent leads of cardiac implantable electronic devices is often achieved by venous cutdown of the cephalic vein, or by "blind" puncture of the subclavian vein using anatomical landmarks, or by fluoroscopy-assisted methods. METHODS: We have retrospectively analyzed our clinical experience to verify the feasibility, the safety, and efficacy of the adoption of ultrasound-guided puncture/cannulation of the axillary vein for this purpose. RESULTS: Nine hundred eighty-seven leads were placed during 548 consecutive procedures, accessing the axillary vein in the infraclavicular area using real-time ultrasound guidance. Venipuncture was successful in 99.8% of cases. The access time was 11 seconds (range 4-580). We recorded three cases of pneumothorax (0.5%), but no hemothorax and no hemo-mediastinum. The incidence of local hematoma was 2.1% (12 cases). No injury to the brachial plexus or to the phrenic nerve was recorded. In a follow-up of 33 months (range 16-39), we observed no cases of "subclavian crush syndrome" (damage of the leads at the level of the thoracic inlet), and the rate of pocket infection/infective endocarditis was 0.7%. CONCLUSION: In our experience, ultrasound-guided puncture/cannulation of the axillary vein for implantation of permanent leads is feasible, effective, and safe. It might be considered as a first option for this procedure.


Sujet(s)
Veine axillaire/chirurgie , Pacemaker , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Repères anatomiques , Femelle , Humains , Mâle , Adulte d'âge moyen , Complications postopératoires , Implantation de prothèse/méthodes , Ponctions , Études rétrospectives , Échographie interventionnelle
3.
Recenti Prog Med ; 110(1): 23-32, 2019 Jan.
Article de Italien | MEDLINE | ID: mdl-30720014

RÉSUMÉ

BACKGROUND: Heart failure (HF) is commonly reported, it is estimated to affect 10% of subjects aged over 70 years. Objectives of this study were to describe clinical and demographic characteristics of patients with HF diagnosis, to analyze therapeutic pathways and to estimate healthcare resources consumption. METHODS: Data on patients aged ≥18 years with a hospitalization discharge diagnosis of HF between 01/01/2010 and 31/12/2014 and in treatment with HF-related drugs were extracted from the administrative databases of the Italian Local Health Unit of Barletta-Andria-Trani (BT). We described the pharmacological treatment prescribed and the use of drugs in combination both at the beginning and at the end of the 12-month follow-up period. The costs analysis was conducted with the perspective of the Italian National Health System. RESULTS: A total of 2 669 patients with HF were enrolled in the study, 1 960 as primary and 709 as secondary diagnosis (average age 77.0±10.4/76.5±11.1 years respectively, 49% and 55% were male, respectively). Mortality during 12 months of follow-up was 46% and 43% respectively. Mostly prescribed pharmacological treatments were diuretics (90.4% of patients with primary HF diagnosis and 79.4% of patients with secondary HF diagnosis), beta-blockers (53.7% and 58.8%, respectively) and aldosterone antagonists (57.5% and 42.5%, respectively); moreover, during the follow-up period, half of the patients presented a switch from the original therapy and 10% of the patients required an add-on. Healthcare resource consumption for patients discharged alive was € 11 872.4 for patients with primary diagnosis and € 12 493.7 for patients with secondary diagnosis of HF. Cost for hospitalizations during follow-up was around € 3 800 (32.3% of total costs) and € 3 600 (29.0% of total costs), respectively. CONCLUSIONS: Our findings are in accordance with what already published, both in a National and International context, on mortality rates in HF patients and related costs for the National Healthcare System. Results from the present study highlight the under-prescriptions of ACEi/ARBs, aldosterone antagonists and beta-blockers in HF patients.


Sujet(s)
Coûts des soins de santé/statistiques et données numériques , Défaillance cardiaque/traitement médicamenteux , Hospitalisation/statistiques et données numériques , Antagonistes bêta-adrénergiques/usage thérapeutique , Sujet âgé , Sujet âgé de 80 ans ou plus , Bases de données factuelles , Diurétiques/usage thérapeutique , Femelle , Études de suivi , Ressources en santé/économie , Ressources en santé/statistiques et données numériques , Défaillance cardiaque/économie , Défaillance cardiaque/mortalité , Hospitalisation/économie , Humains , Italie , Mâle , Adulte d'âge moyen , Antagonistes des récepteurs des minéralocorticoïdes/usage thérapeutique
4.
G Ital Cardiol (Rome) ; 18(2): 150-158, 2017 Feb.
Article de Italien | MEDLINE | ID: mdl-28398368

RÉSUMÉ

BACKGROUND: The aim of this study was to demonstrate the efficacy of a management model to reduce hospitalizations in patients recently admitted for acute decompensated heart failure. METHODS: The management model was based on a close integration between hospital and territory health services. Clinical evaluation, ECG, echocardiographic findings, total body bioimpedance and brain natriuretic peptide serum levels were used to assess clinical stability of patients at discharge and during follow-up. A dedicated nurse (care manager) was involved in patient empowerment, telephone follow-up, check of adherence to therapy and clinical conditions, and management of scheduled evaluations. All hospitalizations occurring prior to or after enrolment in the municipalities involved in the study were considered, as well as the hospitalizations occurring among enrolled patients. RESULTS: A total of 301 patients were enrolled, 226 of them from the Centers of the Puglia Region, Italy. An overall reduction of 6% in total hospitalizations with DRG 127 was observed; the reduction was most evident in the two centers with the smaller reference population (-16% and -26%, respectively). In the group of patients enrolled, an overall reduction in hospital admissions was observed after comparing the period before and after enrolment. A significant increase in the prescription rate of angiotensin-converting enzyme inhibitor/angiotensin receptor blockers, beta-blockers and aldosterone antagonists was also observed. Finally, an overall reduction in the costs for patient management was demonstrated. Similar results were obtained in the two additional Centers of the Basilicata and Lazio Regions. CONCLUSIONS: An integrated management between hospital and territory allows optimization of the management of heart failure patients, with improvement of therapy and reduction in hospitalizations and management costs.


Sujet(s)
Défaillance cardiaque/thérapie , Maladie aigüe , Sujet âgé , Protocoles cliniques , Femelle , Services de soins à domicile , Hospitalisation , Humains , Mâle
5.
Int J Cardiol ; 202: 265-72, 2016 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-26407048

RÉSUMÉ

The clinical use of novel oral anti-coagulant (NOAC) drugs is actually regulated in Italy by bureaucratic restrictions; clinical prescription of NOACs preliminarily requires an online prescription plan which should be compiled on the Italian Drug Agency website. The prescription plan has 1-year validity and clinical condition of the patient treated with NOACs should be reassessed at 1-year prescription renewal. Only few specialists are presently allowed to prescribe NOACs: cardiologists, geriatricians, neurologists, hematologists and internists; general practitioners (GPs) are not currently allowed to prescribe NOACs, although they are the most in proximity with the patient. An even more complex issue is the pertinence of clinical follow-up of patients prescribed with NOACs (control of possible interactions with any new drug, periodical assessment of renal function, management of dose assumption mistakes or drug suspension for occurring surgery before hospitalization for any planned intervention). International statements partially indicate when and how periodical laboratory and clinical follow-up should be performed, but such statements do not often comply with local regulations and do not always take in due consideration the local criticalities and prescription limitations. In May 2015, the regional section of the Italian Association of Hospital Cardiologists of Apulia (ANMCO) therefore convened local representative champions of medical professionals potentially involved in prescription of NOACs, clinical management and follow-up of patients prescribed with NOACs. A final consensus conference formulated a possible shared diagnostic and therapeutic pathway for the clinical management and follow-up of patients assuming NOACs for atrial fibrillation.


Sujet(s)
Anticoagulants/administration et posologie , Fibrillation auriculaire/traitement médicamenteux , Continuité des soins , Administration par voie orale , Consensus , Humains , Italie
6.
Psychoneuroendocrinology ; 31(1): 25-9, 2006 Jan.
Article de Anglais | MEDLINE | ID: mdl-16154295

RÉSUMÉ

Natural benzodiazepine-like compounds (NBDZ) are present in the blood of normal people free of commercial benzodiazepine medication. In this work, we evaluated the levels of NBDZ in maternal/foetal serum during delivery after spontaneous labour (VD) or caesarean section (CS). For both the VD (n=11) and the CS (n=11) groups (VD+CS=22), three blood samples were collected at three different times: the first was collected three days before labour, the second immediately after delivery or at fetal abdominal extraction and the third one was obtained at second day post-partum. NBDZ were measured by radioreceptor binding assay after HPLC extraction and purification while cortisol was measured through radioimmunoassay. In the VD group, a significant increase of NBDZ levels occurred at labour in comparison with the levels found in pre- and post-partum periods. By the contrary, no differences in NBDZ levels were found in the CS group at the three different times. The levels of cortisol in the VD group were found to be higher at labour than that determined at pre- and post-partum. Again no significant changes were found in the CS group. These findings suggest for the first time that labour is associated with a marked increase of NBDZ which could be envisaged as a stress-related event.


Sujet(s)
Benzodiazépines/métabolisme , Parturition/physiologie , Adulte , Benzodiazépines/sang , Césarienne , Chromatographie en phase liquide à haute performance , Femelle , Sang foetal , Foetus/métabolisme , Humains , Hydrocortisone/sang , Grossesse , Dosage par compétition , Stress psychologique/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...